Page last updated: 2024-11-07

tetrahydrocortisol and Diabetes Mellitus, Adult-Onset

tetrahydrocortisol has been researched along with Diabetes Mellitus, Adult-Onset in 2 studies

Research Excerpts

ExcerptRelevanceReference
"To study the oral 11 beta-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM) affected by overweight or obesity."5.69Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity. ( Bianzano, S; Heise, T; Nordaby, M; Peil, B; Plum-Mörschel, L, 2023)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bianzano, S2
Nordaby, M2
Plum-Mörschel, L2
Peil, B2
Heise, T2
Kobayashi, N1
Masuzaki, H1
Tanaka, T1
Nakao, K1

Reviews

1 review available for tetrahydrocortisol and Diabetes Mellitus, Adult-Onset

ArticleYear
[The urinary index of intracellular glucocorticoid reactivation--a novel marker of metabolic syndrome and type 2 diabetes].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Dec-28, Volume: 64 Suppl 9

    Topics: Biomarkers; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Tetrahydrocortisol; Tetrahydrocor

2006

Trials

1 trial available for tetrahydrocortisol and Diabetes Mellitus, Adult-Onset

ArticleYear
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023